Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
November 01, 2016 02:15 ET
|
NOVARTIS FINANCE S.A.
Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared...
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
October 25, 2016 01:00 ET
|
NOVARTIS FINANCE S.A.
Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD...
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
September 18, 2016 16:00 ET
|
NOVARTIS FINANCE S.A.
EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary...
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
August 25, 2016 01:15 ET
|
NOVARTIS FINANCE S.A.
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression...
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
July 19, 2016 01:00 ET
|
NOVARTIS FINANCE S.A.
Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx...
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
May 17, 2016 11:30 ET
|
NOVARTIS FINANCE S.A.
Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the...
Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
April 21, 2016 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow...
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
January 27, 2016 01:00 ET
|
NOVARTIS FINANCE S.A.
Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points...
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
January 17, 2016 16:00 ET
|
NOVARTIS FINANCE S.A.
Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is based...
Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
November 04, 2015 01:00 ET
|
NOVARTIS FINANCE S.A.
Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms....